The HBV Cure working group aims to contribute actively to the identification of new therapeutic targets and antiviral molecules for a functional cure of the HBV virus.
Last updated on 04 July 2024
The HBV Cure working group aims to contribute actively to the identification of new therapeutic targets and antiviral molecules for a functional cure of the HBV virus.
One of the priorities is also to support basic research with translational and clinical research.
– To promote ambitious and innovative research into HBV Cure in France and internationally;
– Leading scientific discussions within the consortium in order to incubate and promote cutting-edge research programmes, combining basic, translational, clinical, social science and public health research;
– Communicate on the Taskforce’s programme and achievements and disseminate knowledge on the HBV Cure theme in order to serve the global perspective of eliminating HBV worldwide.
Fabien Zoulim
Inserm U1052, CHU Lyon – Lyon Cancer Research Centre
Chloé Duquesnay (Coordinatrice des instances scientifiques)
Tounès Saïdi (Cheffe de projet)